17:12 , Jul 20, 2018 |  BC Week In Review  |  Financial News

Allakos spikes after pricing upsized IPO above range

Allakos Inc. (NASDAQ:ALLK) gained $13.25 (74%) to $31.25 July 19 after it raised $128.4 million through the sale of 7.1 million shares at $18 in an upsized IPO. Goldman Sachs, Jefferies and William Blair are...
14:27 , Jul 19, 2018 |  BC Extra  |  Financial News

Allakos spikes after pricing upsized IPO above range

Allakos Inc. (NASDAQ:ALLK) gained $13.25 (74%) to $31.25 Thursday after it raised $128.4 million through the sale of 7.1 million shares at $18 in an upsized IPO. Goldman Sachs, Jefferies and William Blair are underwriters. The...
21:39 , Jun 23, 2018 |  BC Extra  |  Financial News

Latest batch of IPO filings: Rubius, Constellation, Replimune, Allakos

As a busy week for IPO pricings came to a close, several more companies filed for NASDAQ listings late Friday, further stocking an IPO pipeline of companies likely to seek liquidity during a tight calendar...
14:48 , Apr 6, 2018 |  BC Week In Review  |  Clinical News

Allakos reports Phase I data for AK002 in healthy volunteers

Allakos Inc. (San Carlos, Calif.) reported data from a Phase I trial in healthy volunteers showing that single doses of 0.001-1 mg/kg IV AK002 were generally well tolerated. The company is developing the non-fucosylated IgG1...
16:27 , Dec 15, 2017 |  BC Week In Review  |  Financial News

Allakos raises $100M in series B

Allakos Inc. (San Carlos, Calif.) raised $100 million in a series B round led by New Enterprise Associates. Redmile Group, Partner Fund Management, Rock Springs Capital, LifeSci Venture Partners, Samsara BioCapital and an undisclosed institutional...
00:47 , Dec 14, 2017 |  BC Extra  |  Financial News

NEA leads $100M Allakos series B

Allakos Inc. (San Carlos, Calif.) raised $100 million in a series B round led by New Enterprise Associates. Redmile Group, Partner Fund Management, Rock Springs Capital, LifeSci Venture Partners, Samsara BioCapital and an undisclosed institutional...
07:00 , Sep 26, 2016 |  BC Week In Review  |  Clinical News

AK002: Phase I started

Allakos began an open-label, German Phase I trial to evaluate single ascending doses of IV AK002 in about 30 patients. Allakos Inc., San Carlos, Calif.   Product: AK002   Business: Hematology   Molecular target: Undisclosed   Description: Undisclosed...